ISDA: 6VQL

Deposition Date 2020-02-05

Release Date 2020-06-24

Last Version Date 2024-10-09

Entry Detail

PDB ID:

6VQL

Keywords:

TRANSFERASE/TRANSFERASE Inhibitor

Title:

CRYSTAL STRUCTURE OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4-WT) COMPLEX WITH A NICOTINAMIDE INHIBITOR

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

unidentified baculovirus

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.07 Å

R-Value Free:

0.27

R-Value Work:

0.24

R-Value Observed:

0.24

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Interleukin-1 receptor-associated kinase 4
Gene (Uniprot):IRAK4
Chain IDs:A, B, C, D
Chain Length:305
Number of Molecules:4
Biological Source:Homo sapiens

UniProt ID:Q9NWZ3 Pfam ID:PF07714

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
SEP	A	SER	modified residue
TPO	A	THR	modified residue

Ligand Molecules

R7S

SO4

Primary Citation

Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis.

Nair, S, Kumar, S.R, Paidi, V.R, Sistla, R, Kantheti, D, Polimera, S.R, Thangavel, S, Mukherjee, A.J, Das, M, Bhide, R.S, Pitts, W.J, Murugesan, N, Dudhgoankar, S, Nagar, J, Subramani, S, Mazumder, D, Carman, J.A, Holloway, D.A, Li, X, Fereshteh, M.P, Ruepp, S, Palanisamy, K, Mariappan, T.T, Maddi, S, Saxena, A, Elzinga, P, Chimalakonda, A, Ruan, Q, Ghosh, K, Bose, S, Sack, J, Yan, C, Kiefer, S.E, Xie, D, Newitt, J.A, Saravanakumar, S.P, Rampulla, R.A, Barrish, J.C, Carter, P.H, Hynes Jr, J.Show

Acs Med.Chem.Lett. 11 1402 1409 (2020)

PMID: 32676146 DOI: 10.1021/acsmedchemlett.0c00082

Abstact

IRAK4 is an attractive therapeutic target for the treatment of inflammatory conditions. Structure guided optimization of a nicotinamide series of inhibitors has been expanded to explore the IRAK4 front pocket. This has resulted in the identification of compounds such as 12 with improved potency and selectivity. Additionally 12 demonstrated activity in a pharmacokinetics/pharmacodynamics (PK/PD) model. Further optimization efforts led to the identification of the highly kinome selective 21, which demonstrated a robust PD effect and efficacy in a TLR7 driven model of murine psoriasis.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form